section name header

Pronunciation

i-pra-TROE-pee-um

Classifications

Therapeutic Classification: allergy, cold and cough remedies, bronchodilators

Pharmacologic Classification: anticholinergics

Indications

REMS


Unlabeled Use:
  • Inhaln: Adjunctive management of bronchospasm caused by asthma.

Action

  • Inhaln: Inhibits cholinergic receptors in bronchial smooth muscle, resulting in decreased concentrations of cyclic guanosine monophosphate (cGMP). Decreased levels of cGMP produce local bronchodilation.
  • Local application inhibits secretions from glands lining the nasal mucosa.

Therapeutic effects:
  • Inhaln: Bronchodilation without systemic anticholinergic effects.
  • Decreased rhinorrhea.

Pharmacokinetics

Absorption: Minimal systemic absorption (2% for inhalation solution; 20% for inhalation aerosol; <20% following nasal use).

Distribution: 15% of dose reaches lower airways after inhalation.

Metabolism/Excretion: Small amounts absorbed are metabolized by the liver.

Half-Life: 2 hr.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
Inhalation1–3 min1–2 hr4–6 hr
Intranasal15 minunknown6–12 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, palpitations

Derm: rash

EENT: blurred vision, sore throat,

nasal only

epistaxis, nasal dryness/irritation

GI: GI irritation, nausea

Neuro: dizziness, headache, nervousness

Resp: bronchospasm, cough

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Atrovent HFA

Code

NDC Code